Stifel Reiterates Buy on Cue Biopharma, Maintains $8 Price Target
Portfolio Pulse from richadhand@benzinga.com
Stifel analyst Stephen Willey reiterated a Buy rating on Cue Biopharma (NASDAQ:CUE) and maintained an $8 price target.
June 15, 2023 | 12:42 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Stifel analyst Stephen Willey reiterated a Buy rating on Cue Biopharma and maintained an $8 price target.
The reiteration of a Buy rating by Stifel analyst Stephen Willey on Cue Biopharma, along with maintaining an $8 price target, indicates a positive outlook for the company's stock in the short term. This news is highly relevant and important for investors in CUE, as it reflects the analyst's confidence in the company's potential growth.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100